Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction

GÜR S., Kadowitz P. J., Hellstrom W. J. G.

CURRENT PHARMACEUTICAL DESIGN, cilt.16, sa.14, ss.1619-1633, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 16 Sayı: 14
  • Basım Tarihi: 2010
  • Doi Numarası: 10.2174/138161210791164162
  • Dergi Adı: CURRENT PHARMACEUTICAL DESIGN
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1619-1633
  • Anahtar Kelimeler: Activators, erectile function, nitric oxide, PDE5, soluble guanylate cyclase, stimulators, treatment, NITRIC-OXIDE SYNTHASE, RABBIT CORPUS CAVERNOSUM, URINARY-TRACT SYMPTOMS, INHIBITS NEOINTIMA FORMATION, SMOOTH-MUSCLE RELAXATION, HEALTHY MALE-VOLUNTEERS, CINACIGUAT BAY 58-2667, CYCLIC-GMP FORMATION, CARBON-MONOXIDE, PULMONARY-HYPERTENSION
  • Ankara Üniversitesi Adresli: Evet

Özet

Nitric oxide (NO)-sensitive soluble guanylyl cyclase (sGC) is the receptor that catalyzes the formation of the intracellular messenger cyclic guanosine monophosphate (cGMP). Binding of the physiological activator, NO, to the reduced heme moiety of sGC increases the conversion of guanosine triphosphate (GTP) to cyclic GMP (cGMP) and engages crucial effector systems such as protein kinases, phosphodiesterases, and ion channels. The development of compounds that activate sGC independent of NO release has therapeutic implications. Recent studies have demonstrated the potential use of heme-dependent sGC stimulators (e.g. YC-1, BAY 41-2272, BAY 41-8543, BAY 63-2521, CFM-1571 and A-350619) and heme-independent sGC activators (e. g. BAY 58-2667, HMR-1766, S-3448, A-778935) in the treatment of cardiovascular diseases.